Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FMS 
Fresenius Medical Care Corporation (FMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: FMS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30.83
1 Year Target Price $30.83
| 1 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.44% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.77B USD | Price to earnings Ratio 19.34 | 1Y Target Price 30.83 |
Price to earnings Ratio 19.34 | 1Y Target Price 30.83 | ||
Volume (30-day avg) 6 | Beta 0.86 | 52 Weeks Range 18.43 - 29.71 | Updated Date 08/29/2025 |
52 Weeks Range 18.43 - 29.71 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 3.13% | Basic EPS (TTM) 1.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.5 | Actual 0.91 |
Profitability
Profit Margin 3.36% | Operating Margin (TTM) 8.23% |
Management Effectiveness
Return on Assets (TTM) 3.03% | Return on Equity (TTM) 5.72% |
Valuation
Trailing PE 19.34 | Forward PE 10.91 | Enterprise Value 25034601970 | Price to Sales(TTM) 0.76 |
Enterprise Value 25034601970 | Price to Sales(TTM) 0.76 | ||
Enterprise Value to Revenue 1.1 | Enterprise Value to EBITDA 6.79 | Shares Outstanding 586827008 | Shares Floating 209224328 |
Shares Outstanding 586827008 | Shares Floating 209224328 | ||
Percent Insiders - | Percent Institutions 7.96 |
Upturn AI SWOT
Fresenius Medical Care Corporation
Company Overview
History and Background
Fresenius Medical Care was founded in 1996 through the merger of Fresenius AG's dialysis division and National Medical Care, Inc. It has grown to become a leading provider of dialysis products and services.
Core Business Areas
- Dialysis Services: Provides dialysis treatment to patients with chronic kidney failure through a global network of dialysis clinics.
- Dialysis Products: Develops, manufactures, and distributes a wide range of dialysis-related products, including dialysis machines, dialyzers, and related disposables.
- Healthcare Services: Offers a range of other healthcare services, including acute dialysis, vascular access services, and pharmacy services.
Leadership and Structure
Helen Giza serves as the Chief Executive Officer. The company has a global organizational structure with regional divisions responsible for specific geographic areas.
Top Products and Market Share
Key Offerings
- Dialysis Machines (5008S, 6008 CAREset): These machines are used in dialysis clinics to filter patients' blood. Fresenius has a significant market share globally. Competitors include Baxter, Nikkiso, and B. Braun. Fresenius captures a substantial portion of revenue from these devices.
- Dialyzers (FX CorDiax series): These filters remove waste and excess fluids from the blood during dialysis. Fresenius is a leading supplier of dialyzers. Competitors include Asahi Kasei and Toray. These products contribute significantly to the company's revenues.
- Dialysis Services (Clinic Operations): Fresenius operates a large network of dialysis clinics globally, providing treatment to patients with kidney failure. The services segment contributes the largest portion of the company's revenue. Competitors include DaVita and U.S. Renal Care.
Market Dynamics
Industry Overview
The dialysis services and products market is driven by the increasing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally. The market is characterized by technological advancements, regulatory oversight, and reimbursement pressures.
Positioning
Fresenius Medical Care is a dominant player in the dialysis market due to its extensive clinic network, broad product portfolio, and global presence. Its competitive advantage stems from economies of scale, brand recognition, and technological innovation.
Total Addressable Market (TAM)
The global dialysis market is expected to reach hundreds of billions of dollars. Fresenius is well-positioned to capture a significant share of this market due to its comprehensive service and product offerings.
Upturn SWOT Analysis
Strengths
- Global market leader
- Extensive dialysis clinic network
- Comprehensive product portfolio
- Strong brand recognition
- Established relationships with healthcare providers
Weaknesses
- Exposure to reimbursement pressures
- High debt levels
- Operational inefficiencies in some regions
- Vulnerability to regulatory changes
Opportunities
- Expanding dialysis services in emerging markets
- Developing innovative dialysis products and technologies
- Acquiring smaller dialysis providers
- Leveraging data analytics to improve patient outcomes
Threats
- Increasing competition from other dialysis providers
- Pricing pressures from payers
- Adverse regulatory changes
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- DVA
- BAX
- USRN
Competitive Landscape
Fresenius competes with DaVita primarily in dialysis clinic operations. Baxter provides dialysis equipment and solutions. Each competitor has relative strengths in specific product lines or geographic regions.
Major Acquisitions
NxStage Medical
- Year: 2019
- Acquisition Price (USD millions): 2000
- Strategic Rationale: Expanded Fresenius's portfolio of dialysis products and broadened access to home dialysis therapies.
Growth Trajectory and Initiatives
Historical Growth: Fresenius has experienced consistent growth in revenue and earnings over the past decade, driven by the increasing demand for dialysis services and products.
Future Projections: Analysts expect Fresenius to continue growing, driven by the aging global population and increasing prevalence of kidney disease. However, growth may be tempered by reimbursement pressures and competition.
Recent Initiatives: Fresenius has been focused on expanding its presence in emerging markets, developing new dialysis technologies, and improving operational efficiency.
Summary
Fresenius Medical Care is a leading provider of dialysis products and services with a strong global presence. The company benefits from increasing prevalence of kidney disease, but faces reimbursement pressures. Its expansion into emerging markets and innovative product development are key growth drivers. Monitoring regulatory changes and managing competition are essential for continued success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Analyst reports, Market research reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fresenius Medical Care Corporation
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-09-19 | Chair of Management Board & CEO Ms. Helen Giza | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 112445 | |
Full time employees 112445 | |||
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, physician nephrology, ambulant treatment, and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.